Phase 2 Advanced Melanoma trials recruiting now

All Advanced Melanoma trials, every phase

Other phases for Advanced Melanoma

Phase 2 Advanced Melanoma trials

• A Clinical Study of T3011 in Subjects With Advanced Melanoma
  NCT06214156 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Phase II Trial of LM103 in Advanced Melanoma
  NCT07310784 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 16 locations
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
  NCT06594991 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
  NCT07099430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
  NCT05969860 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
  NCT06295159 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
  NCT05663775 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
  NCT06697301 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 107 locations
• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
  NCT07504796 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.